Press Room

Press Clipping / Mar 22, 2018

Five Minutes with Marco Gil - DCAT WEEK’18

TKS, TeckoScienze Publisher, March 22, 2018

Marco Gil picture Hovione Senior VP Sales and Marketing

Marco Gil

Co-CEO, Senior VP - Sales & Marketing

Marco Gil has a degree in Chemical Engineering and a Ph.D. in Chemistry from the Technical University of Lisbon.
 
In 2007 he joined Hovione as an Associate Engineer in the R&D Particle Design area. In May 2011 he was appointed as a Director of R&D Process Chemistry. He has held several management responsibilities, including Site General Manager of the Hovione site in New Jersey, US. From 2017 to 2022, Marco held leadership positions in Sales.
 
Since May 2022 he is the Senior Vice-President of Sales & Marketing at Hovione.

 

 

 

 

PH: How is business right now?

Gil: Business is going well. The CDMO industry is quite busy, not just Hovione. It comes naturally from the good environment that investors found in the biotech sector overall, so there are many programmes ongoing in development. Business is well funded, there is a lot of activity and CDMOs benefit from that. Also, large pharma continues to divest manufacturing assets. The trends of recent years remain and I think they will continue for the next months. The off-patents business is growing too. There is a lot of interest in niche, specialised APIs with specific properties from a physical standpoint.

PH: What specialised technologies are you investing in?

Gil: Spray drying is one of our core technologies,...

 

Read the full interview

Also in the Press Room

See All

Integrated approach simplifies development, reduces risk, and supports scalable manufacturing. Hovione and Industrial Design Consultancy Ltd.’s (IDC) lead single-use nasal dry powder device is now available for commercial partnerships. Hovione and IDC have completed the device design and established initial device manufacturing and supply capability, enabling pharmaceutical partners to leverage existing capsule filling infrastructure. This approach simplifies development, reduces cost and risk, and helps shorten timelines to the clinic and commercialization. “This milestone marks an important step in the evolution of our collaboration with IDC — from device innovation to a fully integrated intranasal drug delivery platform,” said Márcio Temtem, Ph.D., Vice President, Strategic Business Management, Hovione. “As the industry looks for faster, more reliable ways to bring complex therapies to patients, integration becomes critical. By bringing together nasal particle engineering science, formulation manufacturing and filling, and device technologies into a single offering, we enable a more seamless and predictable development journey, accelerating the path to market for intranasal therapies.” The nasal delivery device enables broad and targeted nasal deposition flexibility while delivering maximum usability and reliability. With a patented design and manufacturing process established, the platform is available for partnering with pharmaceutical companies on an exclusive basis as part of Hovione’s integrated offering for inhalation and nasal drug development and manufacturing. Additionally, IDC’s Managing Director, Stephen Knowles Ph.D., said the companies are now “well-advanced” with the development of a multi-use device to support an even wider range of therapies and patient needs. Read the full article at ContractPharma.com    

Press Clipping

Hovione, IDC Launch Intranasal Drug Delivery Platform

May 07, 2026